In combination with the adjuvant sargramostim, STEMVAC in patients with advanced HER2-negative breast cancer was found to be safe and to trigger a high level of sustained type I T-cell response in phase 1 clinical trials (Disis et al., 2022). This evidence concerns the gene ERBB2 and breast cancer.